Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
This report contains market size and forecasts of Insulin API in global, including the following market information:
Global Insulin API Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Insulin API Market Sales, 2017-2022, 2023-2028, (Kg)
Global top five Insulin API companies in 2021 (%)
The global Insulin API market was valued at 1796.1 million in 2021 and is projected to reach US$ 2175.5 million by 2028, at a CAGR of 2.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Regular Human Insulin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Insulin API include Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, Ganlee, United Laboratory, Biocon, Amphastar and Wockhardt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Insulin API manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Insulin API Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Insulin API Market Segment Percentages, by Type, 2021 (%)
Regular Human Insulin
Insulin Analogue
Global Insulin API Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Insulin API Market Segment Percentages, by Application, 2021 (%)
Fast-Acting
Premix
Long-Acting
Global Insulin API Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kg)
Global Insulin API Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Insulin API revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Insulin API revenues share in global market, 2021 (%)
Key companies Insulin API sales in global market, 2017-2022 (Estimated), (Kg)
Key companies Insulin API sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
Ganlee
United Laboratory
Biocon
Amphastar
Wockhardt
Julphar Diabetes
Torrent Pharma

LEAVE A REPLY

Please enter your comment!
Please enter your name here